Original Article

You have full text access to this OnlineOpen article

Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer

  1. Zhiqiang Meng MD, PhD1,
  2. Peiying Yang PhD2,
  3. Yehua Shen MD1,
  4. Wenying Bei RN1,
  5. Ying Zhang RN1,
  6. Yongqian Ge MD1,
  7. Robert A. Newman PhD3,†,
  8. Lorenzo Cohen PhD2,4,*,
  9. Luming Liu MD, PhD1,§,*,
  10. Bob Thornton MPH2,‡,
  11. David Z. Chang PhD5,
  12. Zongxing Liao MD6,
  13. Razelle Kurzrock MD7

Article first published online: 21 AUG 2009

DOI: 10.1002/cncr.24602

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5309–5318, 15 November 2009

Additional Information

How to Cite

Meng, Z., Yang, P., Shen, Y., Bei, W., Zhang, Y., Ge, Y., Newman, R. A., Cohen, L., Liu, L., Thornton, B., Chang, D. Z., Liao, Z. and Kurzrock, R. (2009), Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer, 115: 5309–5318. doi: 10.1002/cncr.24602

Author Information

  1. 1

    International Center of Integrative Oncology, Fudan University Cancer Hospital, Shanghai, China

  2. 2

    The Integrative Medicine Program, Department of General Oncology, The University of Texas M. D. Anderson Cancer, Houston, Texas

  3. 3

    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  4. 4

    Department of Behavioral Science, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  5. 5

    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  6. 6

    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  7. 7

    Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    New Chapter Inc, Brattleboro, Vermont

  2. ‡

    Merck & Co, Inc., Whitehouse Station, New Jersey

  1. §

    Fax: (011) 862164437657

*Department of Behavioral Science, Unit 145, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 21 AUG 2009
  3. Manuscript Accepted: 23 FEB 2009
  4. Manuscript Revised: 20 FEB 2009
  5. Manuscript Received: 3 SEP 2008

Funded by

  • National Cancer Institute. Grant Numbers: CA108084, CA12153031

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (293K)

References

  • 1
    Huang KC. Anesthetic and muscle-relaxing herbs: chan su. In: The Pharmacology of Chinese Herbs. Boca Raton, FL: CRC Press; 1993: 114-115.
  • 2
    Yan ZH, Weng WJ, Gao XM, et al. Chan su. Chin Mater Med. 1979: 425.
  • 3
    Su YH, Nu X. Evaluation of pharmacodynamic effect of pharmaceutical agents of Chan Su. J Beijing Univ TCM. 2001; 24: 51-54.
  • 4
    Su YH, Huang XQ, Zhang DZ, Zhang YN, Xie JM, Linh CQ. HPLC separation and determination of bufadienolide in cinobufacini injection. Chin Tradit Pat Med. 2003; 25: 24-27.
  • 5
    Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008; 8: 36-49.
  • 6
    Hang L. Clinical effect of HuaChanSu injection in combination with chemotherapy in advanced lung cancer. Henan J Oncol. 2002; 15: 70.
  • 7
    Zhongjie S, Chengen P, Guojun W. Clinical observation on HuaChanSu in treating hepatocellular carcinoma after transarterial chemoembolization (TACE). Cancer Prevent and Treat. 2002; 29: 67-69.
  • 8
    Suxia H, Qing Z, Dongxiu L. Clinical effect of HuaChanSu combined with radiotherapy in cancer treatment. Shanxi J Med. 2002; 31: 60-61.
  • 9
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 10
    Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: The M. D. Anderson Symptom Inventory. Cancer. 2000; 89: 1634-1646.
    Direct Link:
  • 11
    Haas M, Askari A, Xie Z. Involvement of Src and epidermal growth factor receptor in the signal-transduction function of Na+/K+-ATPase. J Biol Chem. 2000; 275: 27832-27837.
  • 12
    Kamano Y, Nogawa T, Yamashita A, Hayashi M, Inoue M. Isolation and structure of a 20,21-epoxybufenolide series from “Ch'an Su”. J Nat Prod. 2002; 65: 1001-1005.
  • 13
    Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res. 1995; 19: 549-556.
  • 14
    Zhang L, Wang Q, Lu W, Zhang X, Zheng J, Wang Q. Chemotherapeutic effect of Huachansu on human lung cancer: 106 case report. Chin J Clin Oncol Rehabil. 2001; 8: 90-91.
  • 15
    Haux J, Solheim O, Isaksen T, Angelsen A. Digitoxin, non-toxic concentrations, inhibits proliferation and induces cell death in prostate cancer cell lines. Z Onkol. 2000; 32: 14-20.
  • 16
    Huang YT, Chuedh SC, Teng CM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol. 2004; 67: 727-733.
  • 17
    Jing Y, Ohizumi H, Kawazoe N, et al. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res. 1994; 85: 645-651.
  • 18
    Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. 2001; 12: 475-483.
  • 19
    Kawazoe N, Watabe M, Masuda Y, Nakajo S, Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene. 1999; 18: 2413-2421.
  • 20
    Mckonkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 2000; 60: 3807-3812.
  • 21
    Yeh JY, Huang WJSFK, Wang PS. Effects of bufalin and cinobufalin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate. 2003; 54: 112-124.
    Direct Link:
  • 22
    Hashimoto S, Jing Y, Kawazoe N. Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res. 1997; 21: 875-883.
  • 23
    Xie ZJ, Cai T. Na+-K+-ATPase mediated signal transudation: from protein interaction to cellular function. Mol Interv. 2003; 3: 157-168.
  • 24
    Chen GH. Advances in quality determination, pharmacological studies and clinical application of toad venom. Chin Tradit Herb Drugs. 2001; 32: 184-186.
  • 25
    Cuo XD, Cuei YA, Wang JH, Qin S, Chen HY. The effect of cinobufacini on human gastric neoplasm cell line MGC-80-3. Chin Clin Oncol. 2003; 8: 33-37.
  • 26
    Zhang ZY, Zhang KH, Wang ZW, Zhu JQ, Zhu ZH, Huang DQ. Cytotoxicity of HuaChanSu on 3 digestive tract tumor cells in vitro. Chin Med Pharm Clin. 1999; 15: 28-29.
  • 27
    Cuo XD, Cuei YA, Qin S, Chen HY, Wang JH. Effect of cinobufacini on tumor cell cycle and expression of bcl-2 protein. Mod J Integr Tradit Chin West Med. 2003; 12: 567-568.
  • 28
    Guan J, Zhao XH, Jiang BS, Chen ZW, Qin QY. Preliminary study on the antitumor mechanism of cinobufacini injection. J Penfu Med Coll. 1993; 18: 78-81.
  • 29
    Lin Y, Fu J, Chen XW, Lin DQ. Experimental study on anticancer action of cinobufacini injection for pulmonary carcinoma. J Guangzhou Univ Tradit Chin Med. 2003; 20: 69-71.
View Full Article (HTML) Get PDF (293K)